Clinical Trial: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Non Hodgkin Lymphoma
Study Type: INTERVENTIONAL
Official Title: A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)
Brief Summary:
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Read more